

TABLE OF CONTENTS

	Page
Acknowledgement	I
English Abstract	IV
Thai Abstract	VI
List of Tables	XVI
List of Figures	XXV
Chapter 1 Introduction	
1.1 Hypertension and its treatment	1
1.1.1 Epidemiology	1
1.1.2 Definitions	2
1.1.2.1 Blood pressure	2
1.1.2.2 Classification of hypertension	3
1.1.2.3 White coat hypertension	4
1.1.2.4 Hypertension crisis	6
1.1.2.5 Isolated systolic hypertension	6
1.1.2.6 Hypertension with special groups	6
1.1.3 Blood pressure measurement	11
1.1.3.1 History	11
1.1.3.2 Blood pressure measurement techniques	12
1.1.4 Pathophysiology and etiology	17
1.1.4.1 Essential hypertension or primary hypertension	18


	Page
1.1.4.2 Secondary hypertension	23
1.1.5 Diagnosis	24
1.1.6 Treatment	25
1.1.6.1 Goal BP value	26
1.1.6.2 Pharmacological treatment	26
1.1.6.3 Nonpharmacological treatment	27
1.2 Outcome research	29
1.2.1 Patient satisfaction	30
1.2.2 Quality of life	31
1.3 Pharmaceutical care model	35
1.3.1 Definition	35
1.3.2 Pharmaceutical care in practice	35
1.4 The role of pharmacists as practitioners in primary health care	36
1.5 General aims of the study	44
1.6 Research framework	44
Chapter 2 Methodology	46
2.1 Pilot study	46
2.1.1 Methodology for the pilot study	46
2.1.2 Patient medication record developed	47
2.1.3 Comparison in reading between mercury sphygmomanometer and digital meter	48

	Page
2.1.4 Pro formas' construction	49
2.1.5 Test for reliability and validity	50
2.1.6 Data collection	51
2.2 Main study	51
2.2.1 Study sites	51
2.2.2 Research design	52
2.2.2.1 Treatment group	53
2.2.2.2 Control group	55
2.2.3 Study population and patient selection	55G
2.2.4 Research tools	56
2.2.5 Outcome measurements	56
2.2.6 Data analysis	57
Chapter 3 Results	59
3.1 Results of the pilot study	59
3.1.1 Sample size calculation	59
3.1.2 Sphygmomanometer comparison with digital meter	61
3.1.3 Patient satisfaction	61
Item development and selection	62
Participants	62
Content validity	62
Reliability	63

	Page
3.2.1.5.4 Quality of life (Digit Span test)	108
3.2.1.6 Economic outcome	109
3.2.1.6.1 Cost of medications	110
3.2.1.6.2 Cost of medications on admission	112
3.2.1.7 Conclusion	118
3.2.2 Over 12 months (During July2003-February2004)	123
3.2.2.1 Pharmacist's intervention	123
3.2.2.2 Visits	126
3.2.2.3 Clinical outcomes	127
3.2.2.3.1 Blood pressure control	128
3.2.2.3.2 Blood pressure difference	129
3.2.2.3.3 Results of patient outcomes after 12 months follow-up	130
3.2.2.3.4 Compliance rates	131
3.2.2.3.5 Lifestyle modification	133
3.2.2.4 Humanistic outcomes	134
3.2.2.4.1 Patient knowledge	134
3.2.2.4.2 Patient satisfaction	140
3.2.2.4.3 Quality of life (SF-36)	145
3.2.2.2.4 Quality of life (Digit Span test)	152
3.2.2.5 Economic outcome	153

	Page
3.2.3.4 Conclusions	217
Chapter 4 General discussion and overall conclusions	222
4.1 Design and statistics	222
4.2 Blood pressure outcomes	223
4.3 Compliance	225
4.4 Lifestyle modification	226
4.5 Patient clinical outcomes (visits, hospitalization, death and disabling)	227
4.6 Pharmacist intervention	228
4.7 Cost	230
4.8 Patient knowledge	231
4.9 Patient satisfaction	232
4.10 Patient quality of life (SF-36 and Digit Span test)	234
4.11 Is a pharmacists' contribution, as described here, practical in primary care units in Thailand? What might the impact of the results be on the system as a whole?	237
4.12 Limitations of the study	241
4.13 Conclusions and further research	242
References	243
Appendices	252
Appendix 1 Practice protocol for pharmacist in primary care unit	253

Appendix 2 The reliability and correlation tests of the pro formas	272
Appendix 3 Publications and poster presentations submitted to international conferences	282
Curriculum vitae	308



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่
Copyright© by Chiang Mai University
All rights reserved

LIST OF TABLES

Table	Page
1.1 Classification and management of BP for adults	5
1.2 Techniques for BP measurement	15
1.3 Factors which may influence blood pressure measurement in the clinic setting adapted from reference	16
1.4 Cardiovascular risk factors	25
1.5 Summary of studies of pharmacists' involvement in hypertensive patients	39
3.1 Results of blood pressure readings between the digital meter And sphygmomanometer in 20 patients	61
3.2 Content validity in domains of patient satisfaction pro forma	63
3.3 Domains and items from the interview pro forma	64
3.4 Item analysis and reliability test of patient knowledge	67
3.5 Correlations and coefficient alpha of each subscale item with its own scale (Bold) and with the other scales	68
3.6 Homogeneity of demographic variables between groups at the baseline (N=235)	72
3.7 The response of physicians to the pharmacist's recommendations on modifications to patient medications	73
3.8 Examples of the type of the pharmacist's interventions which were sent for the doctors' considerations	74

Table	Page
3.9 The assessment of hypertensive medications class and the number of hypertensive medications which were used at the pre test and after six months	75
3.10 Numbers of visits to receive medications in the treatment and control groups	76
3.11 Blood pressures at the pre test and after six months in the treatment and control groups	79
3.12 Mean blood pressures and paired differences for all patient (235) and for the group of patients (158) with existing high BP ($\geq 140/90$ mm Hg) at the pre test	80
3.13 Patient clinical outcomes during October 2002-June 2003 in the treatment and the control groups	81
3.14 Patient compliance rates of the treatment and the control groups at the pre test and after six months	83
3.15 Patient compliance rates compared within each group between the pre test and after six months follow-up	83
3.16 The proportion of patients who had made lifestyle modifications after six months compared between the control and the treatment groups	84
3.17 Percent correct responses compared between the treatment and the control groups	88
3.18 Percent correct responses compared between the pre test and after six months in each group	89

Table	Page
3.19 Percent correct responses compared between groups in each domain of patient knowledge constructed questions	90
3.20 Percent of correct answers compared within groups after six months	90
3.21 Means of patient satisfaction at the pre test and after six months in the treatment and the control groups	93
3.22 The results between groups when patient satisfaction items grouped by each domain	94
3.23 The results of patient satisfaction when compared between the pre test and after six month shown by each domain	94
3.24 Descriptive statistics of SF-36 at the pre test and after six months for the treatment group	103
3.25 Descriptive statistics of SF-36 at the pre test and after six months for the control group	104
3.26 Means SF-36 scores for the treatment and the control groups at the pre test and after six months	105
3.27 Comparison of mean scores within each group for the pre test and after six months	105
3.28 The percentage responses of Health Reported Transition compared between the treatment and the control groups and compared within each group	106

Table	Page
3.29 Mean scores of the Digit Span test compared between the treatment and the control groups and compared within each group between the pre test and after six months	109
3.30 Total costs of all medications, medications for hypertension and medications for non hypertension compared between the treatment and the control groups over nine months follow up	113
3.31 Total costs of all medications compared within each group and between the treatment and the control groups	114
3.32 Total costs of hypertension medications, number of patients who received prescriptions in each month and total costs of medication per patient compared between groups	114
3.33 Total costs of non hypertension medications, number of patients who received prescriptions in each month and total costs of medications per patient compared between groups	115
3.34 Costs of medications and number of hospitalizations during October02-June03	115
3.35 The response of physicians to the pharmacist's recommendations on modification of patient medications during July 03 – February 04	124
3.36 Examples of pharmacist's interventions sent for doctors' consideration	125
3.37 Assessment of hypertensive medications class and the number of hypertensive medications which were used after 12 months	126

Table	Page
3.38 Numbers of visits to receive medications in the treatment and the control groups	127
3.39 Blood pressures at the pre test and after 12 months in the treatment and the control groups	129
3.40 Mean blood pressures and paired differences for all patients (235) and for the group of patients (158) with existing high BP ($\geq 140/90$ mmHg) at the pre test, compared between the pre test and after 12 months	130
3.41 Patient clinical outcomes during July03-February04 in the treatment and control groups	131
3.42 Patient compliance rates of the treatment group and the control groups	132
3.43 Patient compliance rates compared within each group between the pre test and after 12 months follow up	132
3.44 The proportion of patients who had made lifestyle modifications after 12 months compared between the treatment and the control groups	133
3.45 Percent correct response compared between the treatment and the control groups between the pre test and after 12 months	137
3.46 Percent correct response compared between the pre test and after 12 months in each group	138
3.47 Percent correct response compared between groups in each domain of patient knowledge constructed questions	139
3.48 Percentage of correct answers compared within group after 12 months	139

Table	Page
3.49 Means and mean ranks of patient satisfaction compared between groups and between the pre test and after 12 months in the treatment and the control groups	143
3.50 The results between groups showing which patient satisfaction items were grouped by each domain	144
3.51 The results of patient satisfaction compared between the pre test and after 12 months shown by each domain	144
3.52 Descriptive statistics of SF-36 in the pre test and after 12 months for the treatment group	148
3.53 Descriptive statistics of SF-36 in the pre test and after 12 months for the control group	149
3.54 Mean SF-36 scores for the control and treatment groups in the pre test and after 12 months follow up	150
3.55 Comparison of mean scores within each group for the pre test and after 12 months follow up	150
3.56 The percentage responses of Health Reported Transition compared between the control and the treatment groups and compared within each group	151
3.57 Mean scores of Digit Span test compared between the control and the treatment groups and compared within each group between the pre test and after 12 months	153

Table	Page
3.58 Total costs of all medications during July03-February04 compared between groups	157
3.59 Total costs of all medications compared within each group and between the treatment and the control groups	158
3.60 Total costs of hypertension medications compared within each group and between the treatment and the control groups	158
3.61 Total costs of non hypertension medications compared within each groups and between the treatment and the control groups	159
3.62 Costs of medications and number of hospitalization during July03-February04	159
3.63 The response of physicians to the pharmacist's recommendations on modification of patient's medications over 12 months	168
3.64 Numbers of visits to receive medications in the treatment and the control groups	169
3.65 BP control compared between groups at each period of time measurement and a covariate	172
3.66 Results of proportions of patients having BP control compared within each group across three times; the pre test, after six months and after 12 months	173
3.67 Mean BPs comparison by 3x2 factorial ANOVA for 235 hypertensive Patients	178

Table	Page
3.68 Patient clinical outcomes during October 2002-February 2004 in the treatment and the control groups	179
3.69 Compliance rates compared between the treatment and control groups	181
3.70 Patient compliance rates comparison in the treatment and the control groups across three times	181
3.71 Lifestyle modification compared between groups across three times	184
3.72 The proportion of patients who had made lifestyle modifications after 12 months compared between the control and the treatment groups and pairwise comparison between the pre test, after six and after 12 months in each group	184
3.73 Percent correct response compared between the control and treatment groups	188
3.74 Percent correct response compared between the pre test, after six and after 12 months in each group	189
3.75 Percent correct response compared between groups in each domain of patient knowledge constructed questions	191
3.76 Mean of patient satisfaction compared between the control and treatment groups	196
3.77 The results between groups where patient satisfaction items were grouped by each domain and pairwise follow up results in each group over 3 times by Grabriel test	197

Table	Page
3.78 Mean SF-36 scores for the control and treatment groups at the pre test after six and after 12 months	200
3.79 The percentage responses of Health Reported Transition compared between the control and the treatment groups and compared within each group	203
3.80 Mean scores of Digit Span test compared between the treatment and the control groups and compared within each group across the pre test, after six and 12 months	206
3.81 Total costs of all medication, medications for hypertension and medication for non hypertension compared between the treatment and the control groups during October 2002-February 2004	211
3.82 Total costs of all medications compared within each group and between the treatment and the control groups	212
3.83 Total costs of hypertension medications compared within each group and between the treatment and the control groups	213
3.84 Total costs of non hypertension medications compared within each group and between the treatment and the control groups	214
3.85 Costs of medications and number of hospitalizations during October 02-February04	214

LIST OF FIGURES

Figures	Page
1.1 Example of ambulatory BP monitoring trace with normal nocturnal dip	3
1.2 Hales making manometric measurements from the carotid artery of a horse in 1733	12
1.3 Sounds heard with application of the stethoscope over the palpable artery	17
1.4 The regulation of BP within the cardiovascular system	18
1.5 Research framework	45
3.1 Percentage responses for Health Reported Transition between the control and the treatment groups at the pre test	107
3.2 Percentage responses for Health Reported Transition between the control and the treatment groups after six months	107
3.3 Total costs of medications in each group during the period October02-June03	116
3.4 Hypertension costs of medications in each group during the period October02-June03	116
3.5 Non hypertension costs of medications in each group during the period October 02-June03	117
3.6 Summary of the process for the study during the first six months	121
3.7 Summary of the significant outcome results after six months	122
3.8 Percentage responses for Health Reported Transition between the control and the treatment groups at the pre test	151

Figures	Page
3.9 Percentage responses for Health Reported Transition between the control and the treatment group after six months	152
3.10 Total costs of all medications during July03-February04	160
3.11 Total costs of hypertension medications during July03-February04	160
3.12 Total costs of non hypertension medications during July03-February04	161
3.13 Summary of the process for the study over a whole year	165
3.14 Summary of the significant outcome results after 12 months	166
3.15 Means of blood pressure control in 235 patients across the pre test, after six months and after 12 months	174
3.16 Means of blood pressure control in 158 patients across the pre test, after six months and after 12 months	174
3.17 Illustration of the significant interaction results of role emotional subscale	202
3.18 Percentage responses for Health Reported Transition between the control and the treatment groups after six months	204
3.19 Percentage responses for Health Reported Transition between the control and the treatment group after 12 months	204
3.20 Total costs of all medications during 17 months, October 02-February 04	215
3.21 Total costs of hypertension medications during 17 months, October 02-February 04	215
3.22 Total costs of non hypertension medications during 17 months, October 02-February 04	216
3.23 Summary of the outcomes after 12 months by multiple comparisons	221